IBT (D) : Eckert & Ziegler BEBIG releases a new version of the PSID software at the ESTRO 31 in Barcelona

Seneffe, Belgium, May 10, 2012, Eckert & Ziegler BEBIG has announced today, that it is launching PSID 5.0, the new version of its treatment planning system, at the ESTRO 31 Congress (European Society for Radiation & Oncology) held in Barcelona on May 9-13, 2012.

PSID (Permanent Seed Implant Dosimetry) is a modern software application used for seed implantation in brachytherapy. The new version includes major improvements, as well as new and unique features that makes treatment planning fast and accurate and supports new developments in brachytherapy.

PSID 5.0 offers the new and exclusive feature of image fusion that can also be performed with live ultrasound images, and supports focal brachytherapy procedures and precise transperineal focal biopsies. Other functions that have been integrated in PSID 5.0 to improve the treatment planning process include: support of variable spacing seeds, planning with two different seed activities and automatic contour tracing.

The Eckert & Ziegler BEBIG PSID software offers a complete solution for preplanning, interactive online planning and post plan evaluation, with 2D and 3D visualisation of the implant and comprehensive reports. PSID offers a unique possibility to contour the prostate and organs at risk on live ultrasound images. Moreover, it allows combining different imaging modalities (US, CT or MRI), which can be viewed in single or fusion mode. Dose distributions and DVH (Dose Volume Histogram) parameters are continuously displayed and updated in real time with every change in seed positions. Needle and seed positions can be determined manually, or by inverse planning. Post plan evaluation is performed quickly and precisely with the automatic seed detect and exclusive seed editing options.

"With the development of the new version of the PSID software we want to respond to upcoming trends and set new standards in the treatment planning of LDR (Low Dose Rate) brachytherapy procedures" said Abel Luzuriaga, Managing Director of Eckert & Ziegler BEBIG. "PSID 5.0 offers outstanding user friendliness, is highly intuitive and fail-safe. We are convinced that these advantages will assure a wide usage of the system among current and new customers of Eckert & Ziegler BEBIG, as well as a further market expansion of the company."

At the ESTRO 31, Eckert & Ziegler BEBIG will present PSID 5.0 to the public for the first time. From May 10-12 at its booth n° 800, the company will be holding two short presentations daily (10:30 a.m. and 2:30 p.m.) to inform the public about the unique features of PSID 5.0.

Customers interested in further information may contact customer.support@bebig.eu:
mailto:customer.support@bebig.eu or the local sales representative directly.

About Eckert & Ziegler BEBIG
...Contributing to saving lives!

Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry. Its core business is the treatment of cancer using brachytherapy, a special form of radiation therapy.

Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company headquarters are in Belgium, with a production facility in Germany and subsidiaries throughout Europe and in India. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing of its product line.

The company's products and equipment are intended for use by oncologists, radiologists, urologists, and medical physicists.

Eckert & Ziegler BEBIG employs more than 150 people. The company has been listed on the Euronext stock exchange since April 1997 (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB).

Contact:
Claudia Mihlan
Head of Marketing

Karolin Riehle
Investor Relations
Tel.: +32 (0) 64 520 808
E-mail: ir@bebig.eu:
mailto:ir@bebig.eu
www.bebig.eu:
http://www.bebig.eu/